In oncogenic KRAS-mutated NSCLC mouse model, KRAS mutation increases the expression of Miz1, which in turn suppresses Pcdh10, leading to enhanced cell proliferation and promotion of lung tumorigenesis (Yang et al. 2022). The gene discussed is PCDH10; the disease is non-small cell lung carcinoma.